7
total announcements
MANKIND.NS · 15 min delayed
Mankind Pharma Limited
Mankind Pharma Limited has informed the Exchange about a scheduled investor conference call to discuss Q1FY27 business performance and results on July 30, 2026.
Mankind Pharma Limited
Mankind Pharma Limited has informed the Exchange about the acquisition of 100% stake in Broadway Hospitality Services Private Limited and the incorporation of a wholly owned subsidiary company in Netherlands to act as a Special Purpose Vehicle for holding investments in R&D assets and business development activities focused on treatment of niche therapies.
Mankind Pharma Limited
Mankind Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming no dematerialisation/rematerialisation of shares for the quarter ended June 30, 2026.
Mankind Pharma Limited
Mankind Pharma Limited has informed the Exchange about a copy of a newspaper publication regarding the 35th Annual General Meeting (AGM) of the company, scheduled to be held on August 4, 2026, through video conferencing or other audio-visual means.
Mankind Pharma Limited
Mankind Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 04, 2026. The meeting will consider and adopt the Standalone Audited Financial Statements for the Financial Year ended March 31, 2026, and the Report of the Board of Directors and Auditors thereon. The meeting will also consider and if thought fit, pass resolutions for the re-appointment of Mr. Satish Kumar Sharma as Whole Time Director of the Company, and the ratification of the remuneration of Cost Auditors for the Financial Year 2026-27.
Mankind Pharma Limited
Mankind Pharma Limited has informed the Exchange about a newspaper advertisement regarding its 35th Annual General Meeting scheduled to be held on August 4, 2026.
Mankind Pharma Limited
Mankind Pharma Limited has informed the Exchange regarding the closure of the trading window for designated persons and their relatives due to the declaration of unaudited financial results for the quarter ending June 30, 2026.